Eli Lilly and Company’s (LLY) Buy Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reissued their buy rating on shares of Eli Lilly and Company (NYSE:LLY) in a research note published on Thursday, Benzinga reports. The firm currently has a $1,025.00 price target on the stock.

Other research analysts have also recently issued reports about the company. Bank of America lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a buy rating in a research report on Friday, August 9th. Evercore ISI upgraded shares of Eli Lilly and Company to a hold rating in a research report on Thursday, September 5th. Morgan Stanley restated an overweight rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Truist Financial restated a buy rating and set a $1,000.00 target price (up previously from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Finally, Jefferies Financial Group increased their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a buy rating in a research note on Monday, June 24th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of Moderate Buy and a consensus price target of $977.35.

Eli Lilly and Company Trading Up 0.2 %

Eli Lilly and Company stock opened at $887.16 on Thursday. Eli Lilly and Company has a 52-week low of $531.61 and a 52-week high of $972.53. The company has a market cap of $843.16 billion, a P/E ratio of 130.66, a P/E/G ratio of 2.78 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The business has a 50-day simple moving average of $900.13 and a two-hundred day simple moving average of $847.87.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Analysts predict that Eli Lilly and Company will post 16.49 EPS for the current year.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 93,593 shares of the business’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $918.64, for a total value of $85,978,273.52. Following the sale, the insider now owns 97,153,810 shares in the company, valued at approximately $89,249,376,018.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.13% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Core Wealth Advisors Inc. increased its position in shares of Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares during the last quarter. Lynx Investment Advisory bought a new position in Eli Lilly and Company during the second quarter valued at $32,000. LGT Financial Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at $36,000. Frank Rimerman Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $37,000. Finally, Redmont Wealth Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 1st quarter worth about $40,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.